Background: PDPN is a transmembrane receptor that promotes cell migration, but modifications that regulate its effects are not known. Results: PKA can phosphorylate PDPN, nonphosphorylatable PDPN promotes cell migration, and phosphomimetic PDPN fails to promote cell migration. Conclusion: PKA can phosphorylate PDPN to decrease cell migration. Significance: PDPN effects on cell motility are important for processes including embryonic development and cancer progression.
PDPN
2 (also called OTS8, RTI40, T1␣, aggrus, and gp36) is a transmembrane mucin-like protein that augments tumor cell invasion. PDPN is required for proper lung and lymphatic system development during embryogenesis (1) (2) (3) . However, PDPN expression is also induced by tumor promoters including 12-O-tetradecanoylphorbol-13-acetate, RAS, and Src (4 -6) and is found at the invasive front of many types of cancer (7, 8) . Indeed, PDPN may serve as a cancer biomarker and effective chemotherapeutic target (8 -10) .
PDPN regulates the activities of Rho, ezrin, and other proteins linked to the actin cytoskeleton to mediate filopodia formation, cell motility, invasion, and metastasis (8, 11) . Some proteins that control the actin cytoskeleton can be modified by phosphorylation to affect cell motility. For example, the adaptor proteins Cas, paxillin, and palladin affect remodeling of the actin cytoskeleton and are phosphorylated as a result of oncogenic kinase signaling cascades to promote or inhibit tumor cell motility (12) (13) (14) (15) .
PDPN is a unique transmembrane receptor protein that consists of an N-terminal extracellular domain of about 140 amino acids, a transmembrane domain of about 20 amino acids, and a short intracellular C-terminal domain of about 10 amino acids. The intracellular tail of PDPN contains two serine residues that are conserved in all mammals. However, the function of these two intracellular serines has not been elucidated. Here, we report that these serine residues influence the effects of PDPN on cell motility and intercellular interactions between fibroblasts and tumor cells.
EXPERIMENTAL PROCEDURES
Kinase Assays-Phosphorylation of the peptide VVMKKIS-GRFSP (synthesized by Proteintech, Chicago, IL), containing the entire intracellular region of mouse PDPN (residues 161-172), was measured using a phosphocellulose paper binding assay (16) . Reaction mixtures contained 300 M peptide in 20 mM Tris-HCl (pH 7.4), 10 mM MgCl 2 , 1 mg/ml bovine serum albumin, 0.25 mM ATP, and [␥-32 P]ATP (100 cpm/pmol). The reactions were initiated by the addition of 25 g/ml PKA (Promega V516A). Aliquots were withdrawn at various time points and quenched by the addition of 10% trichloroacetic acid. The reactions were spotted onto P81 phosphocellulose filters, washed three times with 0.5% phosphoric acid, and analyzed by scintillation counting to determine the picomoles of phosphate transferred.
Generation described previously (15, 17) . The cells passed crisis during standard serial passaging, and genotypes were verified by PCR. Pdpn mutant constructs were produced with the QuikChange II XL site-directed mutagenesis kit according to the manufacturer's protocol (Stratagene 200521). The vector pEF4Pdpn encoding full-length wild type mouse PDPN (PdpnWT) (4, 18) was used as a template. Pdpn(S167A/S171A) encoding nonphosphorylatable PDPN (PdpnAA) was generated with the complementary primer pairs 5Ј-GTTGTTATGAAGAAGAT-TGCTGGAAGGTTCTCGCC-3Ј, 5Ј-GGCGAGAACCTTC-CAGCAATCTTCTTCATAACAAC-3Ј followed by 5Ј-TGG-AAGGTTCGCGCCCTAAAGAGGGCCCTTCGAAGG-3Ј, 5Ј-CCTTCGAAGGGCCCTCTTTAGGGCGCGAACCTT-CCA-3Ј. Pdpn(S167D/S171D) encoding phosphomimetic PDPN (PdpnDD) was generated with the complementary primer pairs 5Ј-GTTATGAAGAAGATTGATGGAAGGTT-CTCGCCCTAAAGAGC-3Ј, 5Ј-GCTCTTTAGGGCGA-GAACCTTCCATCAATCTTCTTCATAAC-3Ј followed by 5Ј-GATGGAAGGTTCGACCCCTAAAGAGCGTTATGAA-GAAGATTGATGG-3Ј, 5Ј-CCATCAATCTTCTTCATA-ACGCTCTTTAGGGGTCGAACCTTCCATC-3Ј. All constructs were verified by sequencing. PdpnWT, PdpnAA, PdpnDD constructs, and the control vector pEF4/V5HisA (Invitrogen) were cotransfected with pBABEpuro into a single expanded PdpnKo cell clone with Lipofectamine 2000 according to the manufacturer's protocol (Invitrogen 11668-027). Transfectants were selected with Zeocin (InvivoGen ant-zn-1p) and puromycin (Calbiochem 540411). This double transfection/ selection technique produces high levels of transgene expression in about 80% or more of surviving cells (4, 15, 19) . Western Blotting-Western blotting was performed as described previously (4, 18) . Protein was resolved by SDS-PAGE, transferred to Immobilon-P membranes (Millipore IH1079562), and incubated with antisera specific for PDPN (University of Iowa Developmental Studies Hybridoma Bank 8.1.1), or GAPDH (Santa Cruz Biotechnology A1978). Primary antiserum was recognized by appropriate secondary antiserum conjugated to horseradish peroxidase and detected using enhanced chemiluminescence (Thermo Scientific 32106). After blotting, membranes were stained with India ink to verify equal loading and transfer.
Evaluation of Cell Growth and Migration-Cell growth and migration were evaluated as described previously (4, 15, 18, 19) . Briefly, cell growth was measured by plating 10,000 cells/well on standard 24-well tissue culture plates (Falcon 353047) and counting cells at the indicated time points in a Coulter counter. For wound healing migration assays, confluent cell monolayers were scratched, and migration was quantitated as the number of cells that entered a 300 ϫ 200-m area in the center of the wound at 18 h. For some experiments, the PKA modulators 8-Br-cAMP (Calbiochem 203800) or H-89 (Calbiochem 371963) were added immediately after wounding. For Transwell invasion assays, 600,000 cells were added to each chamber of 6-well Transwell membranes with an 8-m pore size (Transwell-Clear, Costar 3428), incubated for 24 h, released separately from the top and bottom of the membrane, counted in a Coulter Counter, and quantified as the percentage of cells that migrated from the top of the membrane to the bottom of the membrane.
Video Microscopy-To analyze unopposed movement, PdpnKo cell lines were plated on 35-mm culture dishes at 5% confluence and incubated overnight. To analyze the effects of PdpnKo cells on the movement of melanoma cells in coculture, B16F10 melanoma cells were labeled with 1,1Ј-dioctadecyl-3,3,3Ј3Ј-tetramethylindocarbocyanine perchlorate as described (17, 20, 21) , plated with unlabeled B16F10 cells or PdpnKo cell lines at a 1:100 ratio on 35-mm culture dishes at 85% confluence, and incubated overnight. Medium was then removed and replaced with fresh medium before dishes were mounted on an INUBG2A-ZILCS with UNIV-35 stage top incubator (Tokai Hit, Shizuoka, Japan) maintained at 37°C, 5% CO 2 , and 100% humidity. Images of cells were captured with AxioCam MRm camera at 5-min intervals for 18 (unopposed movement) or 36 h (cocultured melanoma cells) with a 5ϫ CP-Achromat objective on a Zeiss Axiovert 40 CFL inverted microscope or a 10ϫ EC Plan NEOF objective with a Zeiss Axiovert Observer Z1 inverted microscope, respectively. Distance and displacement traveled from the starting point to the end point were measured by tracking the center of the nuclei of motile cells with AxioVision software (version 4.3, Carl Zeiss). The percentage of morphologically intact cells was used to quantitate the survival of cocultured melanoma cells.
Statistical Analysis-Experiments were repeated with similar results and means, errors, and unpaired two-tailed t tests were calculated from representative data sets with Prism (version 4, GraphPad Software).
RESULTS

Phosphorylation of the PDPN Intracellular
Tail by PKA-PDPN activity correlates well between humans and mice (22) . For example, PDPN expression is strongly induced in human (22, 23) and mouse (5, 24) skin cancers. There are 2 conserved serines in the intracellular region of mouse and human PDPN. These serine residues could potentially serve as phosphorylation sites for PKC or PKA. Using a peptide that corresponds to the entire cytoplasmic portion of PDPN, we performed in vitro kinase assays to evaluate the ability of these kinases to phosphorylate these sites. As shown in Fig. 1 , PKA catalyzed the time-dependent phosphorylation of the PDPN cytoplasmic peptide. In contrast, PKC did not phosphorylate the peptide to any significant extent (data not shown).
Nonphosphorylated PDPN Enhances Cell Migration-We generated homozygous null Pdpn knock-out mouse embryonic fibroblasts (PdpnKo cells) to study the effects of PDPN modification on cell behavior. The absence of endogenous PDPN background of these cells facilitated evaluation of how modification of PDPN intracellular serines affected cell growth and motility. These cells were stably transfected with constructs encoding wild type PDPN (PdpnWT), nonphosphorylatable PDPN with both intracellular serines mutated to alanine (PdpnAA), phosphomimetic PDPN with both intracellular serines mutated to aspartate (PdpnDD), or empty vectors (PdpnEF4) as controls. Expression of these transgenes was verified by Western blotting as shown in Fig. 2a .
Although PDPN has been shown to promote cell migration, its effects on cell growth and proliferation are less defined (8 -10) . A role for PDPN in cell growth seemed to emerge on the clear background of homozygous null knock-out cells. As shown in Fig. 2b , expression of wild type (PdpnWT) or nonphosphorylatable (PdpnAA) PDPN appeared to decrease cell growth rates by about 50% when compared with control transfectants (PdpnEF4). Interestingly, this effect was not seen in cells transfected with the phosphomimetic PDPN (PdpnDD) construct.
As expected, wild type PDPN augmented the migration of PdpnKo cells. PdpnWT cells migrated about 50% more than the control transfectants (PdpnEF4) in wound healing migration assays shown in Fig. 2, c and d . However, although expression of the PdpnAA construct did not exceed that of PdpnWT, PdpnAA cells migrated about 40% more than PdpnWT cells in these assays. These results were confirmed by Transwell invasion assays in which PdpnWT cells moved about 4-fold better through 8-m pores than PdpnEF4 cells, and PdpnAA cells moved about 50% more than the PdpnWT cells (Fig. 2e) .
Phosphomimetic PDPN Decreases Cell Migration-Results from wild type (PdpnWT) and nonphosphorylatable (PdpnAA) constructs suggest that PDPN can be phosphorylated to inhibit cell migration. This hypothesis is supported by results from phosphomimetic (PdpnDD) constructs. In contrast to PdpnWT or PdpnAA constructs, phosphomimetic (PdpnDD) Pdpn did not significantly increase cell motility when compared with PdpnEF4 control cells in wound healing migration (Fig. 2,  c and d) or Transwell invasion (Fig. 2e) assays. Interestingly, in contrast to wild type or PdpnAA transfectants, PdpnDD transfection did not significantly decrease cell growth when compared with PdpnEF4 controls (Fig. 2b) . These results suggest that PDPN signaling may convert some metabolic energy used for cell proliferation into processes needed for motility.
Live Cell Imaging of Individual Cells Confirms That PDPN Serine Residue Modifications Affect
Cell Motility-PDPN can promote both collective and individual cell migration in the absence or presence of epithelial-mesenchymal transition (7, 25) . Thus, in addition to wound healing and Transwell assays, live cell imaging was used to investigate the effects of PDPN serine modifications on the motility of individual cells in sparse cultures. These assays also allowed direct measurements of total displacement and distance traveled by individual cells over time.
As with wound healing and Transwell assays cells, PDPN transfectants moved better than control cells, and nonphosphorylatable PDPN increased the motility of these cells more than wild type PDPN. PdpnKo cells transfected with PdpnEF4, PdpnWT, or PdpnAA moved at an average displacement speed of 1.6, 3.7, or 4.2 m/h (Fig. 2f and supplemental Fig. 1, a-c) to travel an average distance of 3.4, 6.2, or 11 m/h, respectively. In contrast, the movement of cells transfected with phosphomimetic PDPN (PdpnDD) was not significantly different from controls (PdpnEF4) when measured by displacement (1.3 m/h) and significantly less than controls when measured by distance (1.9 m/h) ( Fig. 2f and supplemental Fig. 1d ). These data indicate that PDPN can be phosphorylated to decrease both collective and individual cell motility.
Modulators of PKA Activity Affect Migration of Cells Expressing Wild
Type PDPN-Results from kinase assays and site mutants suggest that PKA activation inhibits PDPN-mediated cell migration. As shown in Fig. 3 and supplemental Fig. 2 , the PKA agonist 8-Br-cAMP significantly decreased the migration of cells transfected with wild type PDPN. Conversely, treatment of these cells with the PKA blocker H-89 significantly increased their migration. These data are consistent with the hypothesis that PKA phosphorylates PDPN to decrease cell migration.
PDPN Expression in Fibroblasts Facilitates Neighboring Tumor Cell Migration and Survival-PDPN expression in can-
cer-associated fibroblasts has been linked to increased tumor invasive and metastatic potential (26, 27) . We utilized PdpnKo cells to investigate mechanisms that may underlie the relationship between cancer cells and their neighboring fibroblasts. Melanoma cells that express PDPN as a functionally relevant biomarker and potential chemotherapeutic target were chosen as subjects for this investigation (18) .
Melanoma cells migrated an average distance of about 9.2 m/h when surrounded by other melanoma cells (Fig. 4, a and  b, and supplemental Fig. 3a) . The migration of melanoma cells when surrounded by fibroblasts expressing (PdpnWT cells) was not significantly different from their migration when surrounded by melanoma cells (Fig. 4, a and b, and supplemental  Fig. 3b) . However, melanoma cell migration was decreased by over 50%, to an average distance of only 4.2 m/h, when surrounded by PdpnEF4 control cells (Fig. 4, a and b) . Thus, fibroblasts expressing PDPN appeared to facilitate the migration of neighboring tumor cells better than PDPN-deficient fibroblasts.
In addition to increasing tumor cell motility, PDPN expression in fibroblasts affected the viability of neighboring melanoma cells. As shown in Fig. 4, a and fectants (see supplemental Fig. 3d ). Taken together, these data indicate that PDPN expression levels and phosphorylation status in fibroblasts can affect the motility and viability of neighboring tumor cells.
DISCUSSION
PDPN expression enhances the motility and invasion of several transformed cell types including mammary carcinoma (7, 8) , glioma (28) , and squamous carcinoma cells (29 -31) . PDPN is found at the invasive front of many tumors, which is consistent with its role in promoting invasion (7, 8) . In addition to tumor cells themselves, PDPN is also located on endothelial cells of lymphatic vessels, which can facilitate tumor invasion and metastasis (32, 33) . PDPN expression in cancer-associated fibroblasts has also been linked to tumor aggression and poor prognosis of lung cancers (26, 27, 34, 35) . Consistent with these findings, our results indicate that PDPN expression in fibroblasts can facilitate migration and survival of neighboring tumor cells in the microenvironment. Further elucidation of events underlying this relationship should lead to a greater understanding of fundamental mechanisms that guide stromatumor interactions and how they may be exploited to combat cancer.
Indeed, PDPN presents great potential as a functionally relevant biomarker and chemotherapeutic target (8 -10) . For example, reagents that target PDPN and a PDPN-interacting partner (tetraspanin CD9) can inhibit lung metastasis of CHO cells transfected with PDPN (36, 37) , melanoma tumorigenesis (18) , and glioma progression (38, 39) in mice.
A variety of signaling agents and cytokines can induce PDPN expression and cell motility (5, 6, 40) . For example, the Src tyrosine kinase utilizes the Cas/BCAR1 adaptor protein to augment PDPN expression to promote transformed cell motility required for malignant cells to break out of their microenvironment to become invasive and metastatic (4, 41) .
Elucidating how PDPN promotes cell motility is necessary to understand its role in tumorigenesis and its potential as a chemotherapeutic target. Our findings that PDPN can be phosphorylated to inhibit cell migration and that PDPN expression influences the effects of fibroblasts on neighboring tumor cells shed considerable light on this process. For example, modulators of kinases or phosphatases may be employed to enhance the effects of reagents targeting PDPN to treat a variety of cancers (8 -10) , and possibly other diseases including psoriasis (40) .
